Spark Therapeutics, Inc. Common Stock
ONCE
ONCE was delisted on the 16th of December, 2019.
163 hedge funds and large institutions have $3.15B invested in Spark Therapeutics, Inc. Common Stock in 2017 Q3 according to their latest regulatory filings, with 50 funds opening new positions, 72 increasing their positions, 20 reducing their positions, and 13 closing their positions.
285% more first-time investments, than exits
New positions opened: 50 | Existing positions closed: 13
260% more repeat investments, than reductions
Existing positions increased: 72 | Existing positions reduced: 20
84% more capital invested
Capital invested by funds: $1.71B → $3.15B (+$1.44B)
67% more funds holding in top 10
Funds holding in top 10: 3 → 5 (+2)
28% more funds holding
Funds holding: 127 → 163 (+36)
20% less call options, than puts
Call options by funds: $10.6M | Put options by funds: $13.2M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$53.7M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$49.4M |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$47.4M |
| 4 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$45.9M |
| 5 |
BlackRock
New York
|
+$42.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$65.9M |
| 2 |
Millennium Management
New York
|
-$22.2M |
| 3 |
SMV
Sofinnova Management VIII
Menlo Park,
California
|
-$16.1M |
| 4 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$6.57M |
| 5 |
Victory Capital Management
San Antonio,
Texas
|
-$6.22M |
ONCE Hedge Fund Activity: Q3 2017 in Review
163 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Spark Therapeutics, Inc. Common Stock (ONCE) for Q3 2017, worth a combined $3.15B — up 84% from $1.71B a quarter earlier.
Buyers outnumbered sellers: 50 funds opened new ONCE positions and 13 closed out — a net gain of 37 holders — while 72 added to existing stakes and 20 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $53.7M. The largest seller was Citadel Advisors, cutting an estimated $65.9M.
- 163 institutional investors held Spark Therapeutics, Inc. Common Stock (ONCE) as of Q3 2017, up from 127 in Q2 2017.
- Funds reported $3.15B of Spark Therapeutics, Inc. Common Stock stock for Q3 2017, up 84% quarter-over-quarter.
- 50 funds opened new Spark Therapeutics, Inc. Common Stock positions in Q3 2017 and 13 closed out, a net change of +37 holders.
- The largest Spark Therapeutics, Inc. Common Stock buyer in Q3 2017 was Fidelity Investments, an estimated $53.7M added.
- The largest Spark Therapeutics, Inc. Common Stock seller in Q3 2017 was Citadel Advisors, an estimated $65.9M sold.
Based on aggregated 13F filings for Q3 2017.